SL327
SL327 inhibits MEK1 and MEK2, with IC50 values of 180 nM and 220 nM, respectively.
Product Specifications
CAS Number
[305350-87-2]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
MEK
Type
Reference compound
Related Pathways
MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/SL327.html
Concentration
10mM
Purity
99.57
Solubility
DMSO : 68 mg/mL (ultrasonic) |Ethanol : 0.1 mg/mL (ultrasonic; warming)
Smiles
FC(F)(F)C1=C(/C(C#N)=C(N)/SC2=CC=C(N)C=C2)C=CC=C1
Molecular Formula
C16H12F3N3S
Molecular Weight
335.35
Precautions
H302, H315, H319, H335
References & Citations
[1]Cheng Y, et al. Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22 (10) . pii: E1551.|[2]Selcher JC, et al. A necessity for MAP kinase activation in mammalian spatial learning. Learn Mem. 1999 Sep-Oct;6 (5) :478-90.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MEK1; MEK2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
RC228050L1V 200 µL
CC2D2A (NM_001164720) Human Tagged ORF Clone Lentiviral Particle
Ask
View Details 
283161-01 1 mg
6- (6- (1-Methyl-1H-pyrazol-4-yl) -[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio) quinoline
Ask
View Details 283161-02 2 mg
6- (6- (1-Methyl-1H-pyrazol-4-yl) -[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio) quinoline
Ask
View Details